Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
D967JC00001 DESTINY-Breast07T-DXd given with other treatments in HER2+ metastatic breast cancer: A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY Breast07) | |
|---|---|
| Local Project Reference: | 135544 |
| Principal Investigator | Dr. Rebecca Roylance |
| Drug Class/ Treatment: | Trastuzumab Deruxtecan (T-DXd) - Antibody-Drug Conjugate Monotherapy and/or Combination with Chemotherapy and/or Immunotherapy |
| Patient Population: | HER2-Positive Breast Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
GS-US-586-6144A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer | |
|---|---|
| Local Project Reference: | 305446 |
| Principal Investigator | Dr Elisavet Papadimitraki |
| Drug Class/ Treatment: | Magrolimab - Monoclonal Antibody against CD47 and Macrophage Checkpoint Inhibitor Safety Run-In Cohort 2: Magrolimab + Sacituzumab Govitecan Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel Phase 2 Cohort 1 Arm B: Nab-Paclitaxel or Paclitaxel |
| Patient Population: | Locally Advanced or Metastatic Triple-Negative Breast Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
